Kolistimetatnatrium Accord

Colistimethate sodium, the active ingredient in Kolistimetatnatrium Accord, is a polymyxin antibiotic presented as a solution for injection for intravenous use. It treats severe infections caused by multidrug‑resistant Gram‑negative bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii in hospitalized patients, including those in intensive‑care settings.

GNH USA supplies Kolistimetatnatrium Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Kolistimetatnatrium Accord is employed to combat serious Gram‑negative bacterial infections that are resistant to standard therapies.

- Severe Pseudomonas aeruginosa infections: achieves bacterial eradication in respiratory, urinary and bloodstream sites. - Acinetobacter baumannii infections: provides targeted activity against resistant strains in critically ill patients. - Other multidrug‑resistant Gram‑negative infections: used when alternative agents are ineffective, supporting clinical resolution.

Adverse reactions may occur with intravenous colistimethate sodium and should be monitored.

Common Side Effects: - Nephrotoxicity: rise in serum creatinine or reduced urine output. - Neurotoxicity: paresthesia, dizziness or visual disturbances. - Hypersensitivity: rash, pruritus or mild fever. - Gastrointestinal upset: nausea or vomiting.

Serious or Rare Side Effects: - Acute tubular necrosis: severe kidney injury requiring dialysis. - Respiratory paralysis: especially with high doses or rapid infusion. - Anaphylaxis: sudden airway compromise, hypotension and shock.

Colistimetatnatrium Accord requires careful clinical monitoring due to its toxicity profile.

- Renal function: assess baseline creatinine and monitor regularly. - Neurological status: watch for signs of neurotoxicity such as tingling or confusion. - Concomitant nephrotoxic drugs: avoid or adjust dosing when used together. - Dose adjustment: modify in patients with impaired renal clearance. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Colistimethate sodium can interact with several drug classes, influencing safety or efficacy.

Major Interactions (Avoid): - Aminoglycosides: additive nephrotoxicity and neurotoxicity. - Loop diuretics: increased risk of kidney injury. - Muscle relaxants: potentiation of neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may worsen renal function. - Vancomycin: combined nephrotoxic potential. - Cyclosporine: heightened risk of kidney damage.